|Articles|December 1, 2007

Hepatitis C: Treatment Strategies to Maximize Outcomes
Volume 12
Issue 12 Suppl

Making It Happen: Managed Care Considerations in Vanquishing Hepatitis C

Author(s)John G. McHutchison, MD, Bruce R. Bacon, MD, Glenda S. Owens, RPh, MHA, CDM

Download PDF: Making It Happen: Managed Care Considerations in Vanquishing Hepatitis C

Articles in this issue

over 18 years ago

Article

Participating Faculty

over 18 years ago

Article

Introduction

over 18 years ago

Article

Into the Light: Strategies for Battling Hepatitis C

over 18 years ago

Article

CME/CE POSTTEST

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Making It Happen: Managed Care Considerations in Vanquishing Hepatitis C

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

Teclistamab Plus Daratumumab: MajesTEC-3 Data, Patient Selection, and the Evolving Role of Bispecifics in RRMM

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Making It Happen: Managed Care Considerations in Vanquishing Hepatitis C

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

Teclistamab Plus Daratumumab: MajesTEC-3 Data, Patient Selection, and the Evolving Role of Bispecifics in RRMM